The loan will support general business operations for Cerapedics, including the advancement of the company’s United States regulatory process. Cerapedics also recently announced the preliminary outcomes data from the FDA investigational device exemption clinical trial for i-FACTOR Peptide Enhanced Bone Graft in anterior cervical discectomy and fusion procedures.
The preliminary results indicted the i-FACTOR bone graft met pre-specified primary end points.
More Articles on Orthopedic Devices:
ConforMIS iTotal Knee Shows Promising Clinical Study Results
Ortho Development Gets FDA Clearance for Ovation Tribute Hip Stem
DePuy Synthes Power Tools Launches Anspach EG1 High Speed Electric System
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
